SELENBP1 and hepatocellular carcinoma: However, as the expression of SELENBP1 in HCC and many other cancers is reduced, it promotes tumor malignant transformation and even metastasis (increasing cell motility, promoting cell proliferation, and inhibiting apoptosis only under oxidative stress), shorter overall survival periods, and higher rates of disease recurrence [27].